Cite
Adsit S, Zaldivar ER, Sofen H, et al. Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017;34(7):1772doi: 10.1007/s12325-017-0563-2.
Adsit, S., Zaldivar, E. R., Sofen, H., Dei-Cas, I., Maldonado-García, C., Peñaranda, E. O., Puig, L., Meng, X., Fox, T., & Guana, A. (2017). Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Advances in therapy, 34(7), 1772. https://doi.org/10.1007/s12325-017-0563-2
Adsit, Sandra, et al. "Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials." Advances in therapy vol. 34,7 (2017): 1772. doi: https://doi.org/10.1007/s12325-017-0563-2
Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A. Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017 Jul;34(7):1772. doi: 10.1007/s12325-017-0563-2. PMID: 28589404; PMCID: PMC5504197.
Copy
Download .nbib